查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1225145

子宮內膜異位症市場：按類型、治療（口服避孕藥、促性腺激素釋放激素藥物等）、分銷渠道：2021-2031 年全球機會分析和行業預測

Endometriosis Market By Type, By Treatment (Oral contraceptives, Gonadotropin-releasing hormone medicines, Others), By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 | 商品交期: 2-3個工作天內

價格

2021 年子宮內膜異位症市場價值 12.3981 億美元，預計 2031 年將達到 39.2641 億美元，2022 年至 2031 年的複合年增長率為 12.6% 我在這裡。

子宮內膜異位症是一種子宮內膜組織在子宮外生長的疾病。 子宮內膜異位症被定義為一種疾病，其中類似子宮內膜的組織存在於子宮腔外，例如卵巢、輸卵管和其他盆腔結構。 子宮內膜異位症分為四種類型。 這些包括淺表腹膜子宮內膜異位症、子宮內膜異位症、深部子宮內膜異位症和子宮內膜異位症。 子宮內膜異位症可導致月經來潮、大量出血、排尿疼痛、大便次數增多、便秘、性交時劇烈疼痛、慢性盆腔疼痛和腹脹。 子宮內膜異位症可導致不孕並增加患卵巢癌的風險。

目前尚無治愈子宮內膜異位症的方法，但可以通過藥物治療與子宮內膜異位症相關的疼痛。 促性腺激素釋放激素 (GnRH) 藥物，如 Lupron Depot（亮丙瑞林）、肉桂醛（nafarelin）和 Zoladex（戈捨瑞林）以及口服避孕藥，如 Provera（甲羥孕酮）和 Sprintek（炔雌醇）已用於治療子宮內膜異位症。

推動子宮內膜異位症市場增長的主要因素是對新藥和激素療法的需求不斷增加，全球人口對子宮內膜異位症、活檢和超聲的早期診斷和治療的認識不斷提高。這些包括先進診斷技術的可用性不斷提高方法，如子宮內膜異位症，以及子宮內膜異位症患病率上升。 例如，根據世界衛生組織 (WHO) 2021 年的報告，約有 1.9 億育齡婦女患有子宮內膜異位症，約佔全球女性人口的 10%。

此外，藥物輸送技術的進步、對藥物組合在子宮內膜異位症治療中的應用研究的增加預計將顯示醫療保健業務的增長，從而推動子宮內膜異位症市場的增長。 例如，2022年1月，據Pharmaceutical Technology稱，ObsEva的Yselty（Linzagolix）和Myovant Sciences/Pfizer的Relugolix複方片劑的兩款GnRH拮抗劑將在美國、歐洲五大城市（法國、德國、意大利、西班牙）上市和英國）以及日本七大主要醫藥市場。 Relugolix 將首先在日本上市，計劃於 2022 年進入市場。 這些藥物是在五個最大的歐洲市場和日本推出的首批 GnRH 拮抗劑，將顯著加強子宮內膜異位症市場。

然而，高藥價和低診斷率預計會阻礙子宮內膜異位症市場的增長。 另一方面，新興經濟體未滿足的醫療需求和新興國家有利可圖的商機有望在未來為全球子宮內膜異位症藥物製造商帶來巨大機遇。

此外，全球醫療基礎設施的快速發展、女性生殖健康意識的提高，以及印度和中國等新興國家政府為提高女性健康意識所做的努力，都為支持性市場的增長做出了貢獻。 因此，預計在預測期內將為主要參與者提供有利可圖的市場投資機會。 此外，為發現和開發有效藥物而增加的研發投資、增加政府對子宮內膜異位症治療研究的資助以及發達國家資本收入的顯著增加都在推動市場增長。 例如，2022年3月，美國聯邦政府宣布向國家兒童健康與人類發展研究所（NICHD）撥款9200萬美元，用於資助國防部針對子宮內膜異位症研究的同行評審醫學研究計劃（PRMRP）繼續出資3.7億美元。

此外，主要參與者採用的產品發布、合作夥伴關係、產品批准、合作、併購等關鍵戰略的興起將加強市場對治療子宮內膜異位症的藥物的需求。。 例如，2022 年 8 月，Myovant Sciences 和輝瑞公司宣布，美國食品和藥物管理局 (FDA) 已批准 Myfembree (relugolix 40) 作為一種每日一次的治療藥物，用於治療與中度至重度子宮內膜異位症相關的疼痛。mg，雌二醇 1毫克，醋酸炔諾酮 0.5 毫克）。 這一批准是一個重要的裡程碑，反映了輝瑞和 Myovant 在一個高度未滿足需求的領域對女性健康的承諾。 因此，這些因素正在推動子宮內膜異位症市場的增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資領域
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 中等強度的競爭
  • 市場動態
    • 司機
      • 增加對子宮內膜異位症研究的資助
      • 提高對子宮內膜異位症的認識
    • 約束因素
      • 子宮內膜異位症的治療費用昂貴
    • 機會
      • 增加研發活動和最近的產品批准
  • 分析 COVID-19 對市場的影響

第 4 章子宮內膜異位症市場：按類型

  • 概覽
    • 市場規模和預測
  • 淺表腹膜病變
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 子宮內膜異位症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章子宮內膜異位症市場：按治療

  • 概覽
    • 市場規模和預測
  • 口服避孕藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 促性腺激素釋放激素 (GnRH) 藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章子宮內膜異位症市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 零售藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章子宮內膜異位症市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 歐洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 拉丁美洲其他地區/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測

第8章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年最佳球員排名

第9章公司簡介

  • Abbott Laboratories
  • Consilient Health Limited
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Ltd
  • Abbvie Inc
  • AstraZeneca plc
Product Code: A47225

The endometriosis market was valued at valued at $1,239.81 million in 2021, and is projected to reach $3,926.41 million by 2031, registering a CAGR of 12.6% from 2022 to 2031.

Endometriosis is a type of disease in which endometrial tissue grows outside the uterus. Endometriosis is defined as a condition where tissue similar to the lining of the uterus is found outside of the uterine cavity such as on the ovaries, fallopian tubes, or other pelvic structures. Endometriosis are of four types. These include superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Endometriosis can lead to pain during periods, excessive bleeding, painful urination, frequent bowel movements, constipation, severe pain during sexual intercourse, chronic pelvic pain, and abdominal bloating. Endometriosis can cause infertility and increase the risk of ovarian cancer.

There is currently no cure for endometriosis, however pain associated with endometriosis can be managed with medication. The gonadotropin-releasing hormone (GnRH) medicines such as Lupron Depot (leuprolide), Synarel (nafarelin), Zoladex (goserelin) and oral contraceptive such as Provera (medroxyprogesterone), Sprintec (ethinyl estradiol) are used for the management of endometriosis.

Major factors driving growth of the endometriosis market include rise in demand for novel drugs and hormonal therapies, rise in awareness regarding early disease diagnosis and treatment of endometriosis among global population and increasing availability of advanced diagnostic methods such as biopsy, ultrasound and rise in the prevalence of endometriosis. For instance, according to the world health organization (WHO) 2021 report, about 190 million reproductive-age females have endometriosis, accounting for about 10% of the female population globally.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in advancement in drug delivery technologies, rise in research regarding using combination of drug for the management of endometriosis drives the growth of endometriosis market. For instance, in January 2022, according to pharmaceutical technology, two GnRH antagonists, ObsEva's Yselty (linzagolix) and Myovant Sciences/Pfizer's Relugolix combination tablet, are set to launch across the seven major pharmaceutical markets, the US, five major European markets (France, Germany, Italy, Spain, and the UK) and Japan, in the next two years. Relugolix will launch in Japan first, entering that market in 2022. These medications will be the first GnRH antagonists launched in the five major European markets and Japan, which will bolster the endometriosis market significantly.

However, the high cost of medicine and low diagnostic rate is expected to hamper the growth of the endometriosis market. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for endometriosis medicine manufacturers worldwide in the future.

Moreover, rapidly advancing global healthcare infrastructure, rise in awareness regarding female reproductive health, increasing government initiatives to raise awareness about women's health in developing countries like India, China drives the growth of endometriosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period. In addition, a rise in R&D investments in discovery & development of effective medicine, rise in funding from government for research regarding treatment of endometriosis and significant rise in capital income in developed countries drives the growth of the market. For instance, in March 2022, the U.S. federal government announced $92 million funds to National Institute of Child Health and Human Development (NICHD) and continues to provide $370 million to the Department of Defense's Peer-Reviewed Medical Research Program (PRMRP) for endometriosis research.

Furthermore, the rise in key strategies include product launch, partnership, product approval, collaboration, merger, acquisition adopted by key players strengthen demand of medication for the management of endometriosis in the market. For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant's commitment to women's health in areas of significant unmet need. Hence, such factors drive the growth of the endometriosis market.

The endometriosis market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is classified into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). On the basis of treatment, the market is classified into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. Depending on the distribution channel, it is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Consilient Health Limited, GlaxoSmithKline plc, Merck & Co. Inc, Pfizer Inc, Sanofi India Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the endometriosis market analysis from 2021 to 2031 to identify the prevailing endometriosis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the endometriosis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global endometriosis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Superficial peritoneal lesion
  • Endometriomas
  • Others

By Distribution channel

  • Hospital pharmacy
  • Online pharmacy
  • Retail pharmacy

By Treatment

  • Oral contraceptives
  • Gonadotropin-releasing hormone (GnRH) medicines
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Consilient Health Limited
    • Serum Institute of India Pvt. Ltd.
    • Abbott Laboratories
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • AstraZeneca plc
    • Abbvie Inc
    • Sanofi
    • Sun Pharmaceutical Industries Ltd
    • Torrent Pharmaceuticals Ltd
    • Teva Pharmaceutical Industries Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in funding for research of endometriosis
      • 3.4.1.2. Rise in awareness regarding endometriosis
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of endometriosis medicine
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in R&D activities and recent product approval
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ENDOMETRIOSIS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Superficial peritoneal lesion
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Endometriomas
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: ENDOMETRIOSIS MARKET, BY TREATMENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral contraceptives
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Gonadotropin-releasing hormone (GnRH) medicines
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online pharmacy
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Retail pharmacy
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ENDOMETRIOSIS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Treatment
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Treatment
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Treatment
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Treatment
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Treatment
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Treatment
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Treatment
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Treatment
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Treatment
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Treatment
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Treatment
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Treatment
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Treatment
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Treatment
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Treatment
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Treatment
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Treatment
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Treatment
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Treatment
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Treatment
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Treatment
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Treatment
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Treatment
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Consilient Health Limited
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. GlaxoSmithKline plc
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Merck & Co. Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Pfizer Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Sanofi
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Serum Institute of India Pvt. Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. Sun Pharmaceutical Industries Ltd
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Torrent Pharmaceuticals Ltd
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
  • 9.11. Abbvie Inc
    • 9.11.1. Company overview
    • 9.11.2. Key Executives
    • 9.11.3. Company snapshot
    • 9.11.4. Operating business segments
    • 9.11.5. Product portfolio
    • 9.11.6. Business performance
  • 9.12. AstraZeneca plc
    • 9.12.1. Company overview
    • 9.12.2. Key Executives
    • 9.12.3. Company snapshot
    • 9.12.4. Operating business segments
    • 9.12.5. Product portfolio
    • 9.12.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. ENDOMETRIOSIS MARKET FOR SUPERFICIAL PERITONEAL LESION, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. ENDOMETRIOSIS MARKET FOR ENDOMETRIOMAS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. ENDOMETRIOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. ENDOMETRIOSIS MARKET FOR ORAL CONTRACEPTIVES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. ENDOMETRIOSIS MARKET FOR GONADOTROPIN-RELEASING HORMONE (GNRH) MEDICINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. ENDOMETRIOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. ENDOMETRIOSIS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. ENDOMETRIOSIS MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. ENDOMETRIOSIS MARKET FOR RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. ENDOMETRIOSIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. CHINA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CHINA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CHINA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. JAPAN ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. JAPAN ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. AUSTRALIA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 88. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 89. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 90. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 91. CONSILIENT HEALTH LIMITED: KEY EXECUTIVES
  • TABLE 92. CONSILIENT HEALTH LIMITED: COMPANY SNAPSHOT
  • TABLE 93. CONSILIENT HEALTH LIMITED: PRODUCT SEGMENTS
  • TABLE 94. CONSILIENT HEALTH LIMITED: PRODUCT PORTFOLIO
  • TABLE 95. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 96. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 97. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 98. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 99. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES
  • TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT
  • TABLE 102. MERCK & CO. INC.: PRODUCT SEGMENTS
  • TABLE 103. MERCK & CO. INC.: PRODUCT PORTFOLIO
  • TABLE 104. PFIZER INC.: KEY EXECUTIVES
  • TABLE 105. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 106. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 107. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 108. SANOFI: KEY EXECUTIVES
  • TABLE 109. SANOFI: COMPANY SNAPSHOT
  • TABLE 110. SANOFI: PRODUCT SEGMENTS
  • TABLE 111. SANOFI: PRODUCT PORTFOLIO
  • TABLE 112. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 113. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 114. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 115. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: SERVICE SEGMENTS
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 124. TORRENT PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 125. TORRENT PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 126. TORRENT PHARMACEUTICALS LTD: PRODUCT SEGMENTS
  • TABLE 127. TORRENT PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 128. ABBVIE INC: KEY EXECUTIVES
  • TABLE 129. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 130. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 131. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 132. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 133. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 134. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 135. ASTRAZENECA PLC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ENDOMETRIOSIS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF ENDOMETRIOSIS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN ENDOMETRIOSIS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALENDOMETRIOSIS MARKET
  • FIGURE 10. ENDOMETRIOSIS MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR SUPERFICIAL PERITONEAL LESION, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR ENDOMETRIOMAS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. ENDOMETRIOSIS MARKET, BY TREATMENT, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR ORAL CONTRACEPTIVES, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR GONADOTROPIN-RELEASING HORMONE (GNRH) MEDICINES, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR ONLINE PHARMACY, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR RETAIL PHARMACY, BY COUNTRY 2021-2031(%)
  • FIGURE 22. ENDOMETRIOSIS MARKET BY REGION, 2021
  • FIGURE 23. U.S. ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. CHINA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: ENDOMETRIOSIS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 50. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. MERCK & CO. INC.: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 56. MERCK & CO. INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. MERCK & CO. INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. SANOFI: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. SANOFI: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021
  • FIGURE 63. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 64. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 65. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. TORRENT PHARMACEUTICALS LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 70. TORRENT PHARMACEUTICALS LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 73. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 74. ASTRAZENECA PLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 75. ASTRAZENECA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 76. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2021 (%)